Protara Therapeutics (TARA) Amortizatization of Intangibles (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Amortizatization of Intangibles of -$190000.0 for Q1 2026, down 14.46% year-over-year from -$222112.7 in Q1 2025, and up 40.06% quarter-over-quarter from -$317000.0 in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Amortizatization of Intangibles for 13 consecutive years, with -$190000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 14.46% year-over-year to -$190000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 62.07% YoY), while the FY2025 annual figure was -$1.2 million, down 81.75% from the prior year.
- Amortizatization of Intangibles climbed to -$190000.0 in Q1 2026 per TARA's latest filing, from -$317000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $410000.0 in Q1 2022 and bottomed at -$396000.0 in Q3 2025.
- Historically, Amortizatization of Intangibles has averaged -$83941.2 across 5 years, with a median of -$127000.0 in 2023.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles soared 94.74% — and 2025, when it sank 5128.57%.
- Protara Therapeutics' Amortizatization of Intangibles stood at $108000.0 in 2022, then tumbled by 204.63% to -$113000.0 in 2023, then tumbled by 146.9% to -$279000.0 in 2024, then dropped by 13.62% to -$317000.0 in 2025, then jumped by 40.06% to -$190000.0 in 2026.
- Business Quant data shows TARA's Amortizatization of Intangibles at -$190000.0 in Q1 2026, -$317000.0 in Q4 2025, and -$396000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | 289,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 289,000.00 |
| Mar 31, 2026 | 283,000.00 |
| Dec 31, 2025 | -317,000.00 |
| Sep 30, 2025 | -396,000.00 |
| Jun 30, 2025 | -795,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 259,000.00 |
| Sep 30, 2024 | 254,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 246,000.00 |
| Dec 31, 2023 | 302,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Jun 30, 2023 | 342,000.00 |
| Mar 31, 2023 | 341,000.00 |
| Dec 31, 2022 | 337,000.00 |
| Sep 30, 2022 | 273,000.00 |
| Jun 30, 2022 | 346,000.00 |
| Mar 31, 2022 | 410,000.00 |
| Dec 31, 2021 | 457,000.00 |
| Sep 30, 2021 | 533,000.00 |